

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

August 24, 2021

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Investors Conference Participation- Reg. 30

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find below the details of Analyst/Institutional Investors meet which will be participated by the Company along with the presentation to be made at the same:

Date	Host	Venue/ Mode
August 25 & 26, 2021	Nirmal Bang - Virtual Investors Conference	Audio/ Video Conference

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited

Rhisamelar

Rajesh Shirambekar Head – Legal & Company Secretary

Encl.: as above



RPG LIFE SCIENCES

An ��RPG Company

Investors' Presentation

Disclaimer

This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures, and financial results, are forward looking statements. Forward looking statements are based on certain assumptions and expectations of future events. The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The actual results, performance or achievements, could thus differ materially from those projected in any such forward-looking statements.


The company operates in the Pharmaceutical segment. Some of the historical Profit and loss numbers which are sliced in the investor presentation for certain sales divisions are purely for broader understanding for investors of the business of the company and its growth trajectory. The information contained in these materials has not been independently verified. None of the Company, its Directors, Promoter or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation. The Company undertake no obligation to update or revise any information or the opinions expressed in this presentation as a result of new information, future events or otherwise. Any opinions or information expressed in this presentation are subject to change without notice.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of RPG Life Sciences Limited Limited (the "Company"), nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment therefore. Any person/ party intending to provide finance / invest in the shares/businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorized to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.



RPG Life Sciences Overview

RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space.



Domestic Formulations

Develop, manufacture and market branded formulations in India & Nepal

International Formulations

Develop, manufacture and sell oral solid dosage formulations in the generics and branded generics space across Regulated and Emerging Markets

<u>APIs</u>

Develop, manufacture and sell high value synthetic APIs in the general therapeutic category



Leader in Immunosuppressants



6 Leading Text Book Brands



50+ Markets Presence



3 Manufacturing Facilities







RPG Life Sciences Product Portfolio



International

APIs

Key Products

Formulations Generics - Azathioprine, Sodium Valproate PR, Nicorandil Branded Generics – Siloxogene, Azoran, Mofetyl, Arpimune, Dipsope


Key Products


APIs - Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide, Nicorandil, Pantoprazole, Diphenoxylate

Key Financials, Business Highlights & Strategy



(All figures in Rs. Crores except EPS in Rs.)





Company becomes Debt-free



Long term rating upgraded to A from A-Short term rating upgraded to A1 from A2+

Outlook on long term rating has been retained as Stable.

The rating upgradation factors:

- Considerable improvement in the operating performance on the back of
 - Improvement in sales hygiene
 - Cost rationalisation measures adopted over FY2020 and H1 FY2021.
- > A robust capital structure and strong coverage indicators based on
 - Decline in the company's debt levels
 - Healthy cash flows
 - No major debt-funded capital expenditure (capex)



Business Segment-wise Performance

Domestic Formulations (DF)	 Domestic Formulations contributed 62% to total Sales of FY21 Sustained sales with +ve growth despite Covid headwinds : Deeper Acute Portfolio deceleration, Transplant, Dialysis centres/Clinics closure, smaller companies worse hit etc Product Portfolio rejuvenation - New launches in specialty (Biosimilars) and chronic (Gliptins) segments 	195.8	240.5	242.1	69.9
	 Building Strategic Brand Assets - Life Cycle Management Initiatives (New Line Extensions; New customer segments) 	FY19	FY20	FY21	FY22 Q1
International Formulations (IF)	 International Formulations contributed 21% to total Sales of FY21 UKMHRA approval of our Complex Generic Product Sodium Valproate PR; launched in UK Growth driven by regulated markets. Myanmar, one of our key emerging 	67.1	69.7	80.2	19.5
	markets, faced disruptions due to political instability	FY19	FY20	FY21	FY22 Q1
ΑΡΙ	 API contributed 17% to total Sales of FY21 Covid impacted the demand of our acute portfolio. However thrust on new customer development helped us to prevent sales erosion 	68.2	67.4	67.9	19.1

Net Sales (Rs Crs)

FY19


FY20

FY21 FY22 Q1

<u>Highlights</u>

- Operating in Mass/Mass-specialty and Specialty segments
- Presence in both Acute & Chronic therapy areas
- Leading Text Book Brands Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace
- Leader in Immunosuppressant category
- Good Customer Coverage Cardiologists, Diabetologists, Urologists, Nephrologists, Rheumatologists, Oncologists
- New Product Launches in New Category Biosimilars

Business Strategy



Highlights

- Strong presence in immunosuppressant segment (Azathioprine)
- Footprints across Regulated and Emerging Markets Canada, UK, Germany, France, Australia, South East Asia, Africa
- Long lasting, impeccable supply track record and business relationship with some of the leading generic players of the world
- High Quality and Process orientation making us a preferred partner


Business Strategy



Highlights

- High Value, Low Volume Niche APIs
- Mature Stable Molecules
- Provides backward integration to International Formulations business
- Footprints across geographies LATAM, Iran, Germany, China, South Korea, Bangladesh, Egypt, India, etc
- Strong customer focus Long lasting relationship with Big Pharma and Leading Generic Firms.

Business Strategy



PPG I IFF SCIE

Infrastructure & Backend Capabilities



Manufacturing Facilities

Formulations Unit 1, Ankleshwar



- F1 unit caters to the Domestic and Emerging Markets
- Multipurpose plant with dedicated product lines for Oral Dosage forms including Tablets, Liquids and Powder
- WHO, Kenya, Nigeria approved

Formulations Unit 2, Ankleshwar



- F2 unit caters to the Regulated Markets
- Dedicated product lines for Oral Dosage
- Equipped to handle low RH and low temperature conditions products
- WHO, EUGMP, Canada, Ethiopia, Kenya, Sudan, Nigeria approved

API Unit, Navi Mumbai



- MF1: Multipurpose unit catering to emerging markets including India
- MF2: Dedicated Immunosuppressant facility catering to Regulated markets
- MF3: Multipurpose unit catering to Regulated markets
- WHO, TGA Australia approved

An 🆇 RPG Company

Strong Backend Capabilities

Quality

- All Critical SOPs harmonized through CQA
- Quarterly Internal audit of all plants by CQA
- All critical deviations, change controls and market complaints investigation approved by CQA

Regulatory

- Well established & evolved Regulatory function catering to Canada, UK, EU, Australia and Emerging markets
- Expertise of eCTD submissions
- Integrated Project Management activities



Formulations R&D

- In addition to Formulations Development of IR, have capabilities to develop Modified Release & Complex Generics
- Dossiers Gap Analysis and fulfilment
- Tech Transfer/Site transfer activities
- **GLP compliant Analytical Lab** for Development and Validation of Analytical Methods

Digitization Focus Areas

- Quality Management systems : e-QMS, e-DMS, e-LMS.
- Access to critical manufacturing equipment through IRIS scanner
- All QC instruments attached with **dedicated software** and server
- All stability chambers with software control
- Secondary packing Complies with EUFMD requirement for **Track and Trace.**




Operational Highlights



A passionate call to the entire organization to go all out to ensure continuous availability of our life saving, critical medicines to our patients. Our Plants did not stop even for a single day.

Every patient, who asked for our critical medicines, serviced by door delivery.



Game Changer Customer Connect Initiative Anytime, Anywhere **Doctor Support** 9:27 👖 🖪 🕅 ♥▲ 1 53% Initiative Ms. Falak Jindal My Service Requests COVID-19 One Source Ξ **Industry First** Scientific Update COVID-19 Initiative COVID-19 One Source Scientific Support Scientific Update Support **Range of Services** PATIENT EDUCATION MATERIAL PATIENT EDUCATION MATERIAL CONTACT US >8000 Key Opinion CONTACT US Leaders Ø,

Employee Connect Initiatives

RXR 2.0

Digital Platform for comprehensive Salesforce Operations tracking:

#Customer visits, customer engagement activities, sales performance analytics etc



HR Chatbot for quick resolution of queries related to HR process and company policies



A digital platform for Salesforce Grievance Redressal

RPG LIFE SCIENCES

Initiatives in Plant Operations

e-QMS: Digital Platform to track all 6 Quality parameters

e-DMS: Digital Platform to manage all manufacturing/quality documents


e-LMS: Digital Platform to Track Training Sessions on CGMP

e- Access: Retina Scanning for machine access

All above represent Illustrative list of the initiatives

An 🆇 RPG Company

People Initiatives to build Performance Culture with focus on Happiness



P2G I IFF SCIENCES

Awards & Recognitions



Prestigious Awards from IDMA - Indian Drug Manufacturer's Association in January 2020

(consists of 1000+ pharma companies)



IDMA Quality Excellence Award 2019 (GOLD AWARD)







IDMA Corporate Citizen Award 2019





- Ranked 85 amongst India's 100 Best Companies to Work For 2020
- One of India's Best Workplaces in Biotechnology & Pharmaceuticals by Great Place to Work[®] Institute



An 🆇 RPG Company

Media Recognition

- Not a single day Plant stoppage
- Home Delivery of critical life saving medicines to all the patients

HOME MARKETS COMPANIES OPINION TECH SPECIALS PF PORTFOLIO MULTIMED Business Standard JUSTIN Google slows new hiring due to Covid-19, looks to invest in strategic areas < II > You are here: Home » Companies » News	Business Markets News Portfolio Commodities Mutual Funds Personal Finance Forum Media Earth360 Invest Global Subsc Business Market Coronavirus ponomy Companies Trends IPO Opinion Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More + Home > News > COMPANIES
Word are needed Production of the product of the pharmaceutical industry having the essential commodities tag. the administration Despite the pharmaceutical industry having movement of people and product BS Reporter Mumbai	Overcoming all COVID-19 odds, this pharma company delivered life-saving medicine to patients Yugal Sikri, Managing Director, RPG Life Sciences narrated the unprecedented chaos and disruption his company has to go through to bring a life-saving medication Azathioprine to patients in India.





An **《》RPG** Company